X
- No products in the list
The Endometrial Cancer NGS Panel truNGS® Kit is a comprehensive next-generation sequencing assay designed to detect clinically relevant variants in endometrial cancer. Covering 31 genes and six pharmacogenomics hotspots, the panel identifies single nucleotide variants (SNVs), insertions/deletions (Indels), and copy number variations (CNVs) from DNA isolated from FFPE or fresh frozen tissue.
Built on hybrid capture technology, the panel ensures full exon coverage, enabling both the detection of known mutations and the discovery of novel alterations. The workflow is optimized for Illumina and MGI platforms, requiring only 100–200 ng of DNA and delivering high uniformity and sensitivity (LoD as low as 3.5%).
With integrated bioinformatics and automated reporting, the Endometrial Cancer NGS Panel transforms sequencing data into actionable insights within 1.5 hours. Designed in line with NCCN and ESMO guidelines, this solution empowers molecular diagnostic laboratories and oncology professionals with accurate, reproducible results to support diagnostics, personalized treatment, and translational research.
The truNGS® Endometrial Cancer Panel Kit is specifically curated to address the genetic complexity of endometrial cancer. It covers 31 clinically relevant genes such as TP53, PTEN, KRAS, PIK3CA, MLH1, MSH2, MSH6, PMS2, IDH1, and EGFR, all of which are frequently implicated in tumor development and progression.
In addition, the panel includes six pharmacogenomics hotspots (DPYD, UGT1A1, CYP2D6, MTHFR, TPMT, and CYP2C9) that are directly linked to drug metabolism and treatment response. With a target region of 117 kb and optimized probes, the panel provides high sensitivity and reproducibility, enabling robust detection of SNVs, Indels, and CNVs.
Endometrial cancer is one of the most common gynecological malignancies, with genetic alterations driving tumor initiation and progression. Mutations in TP53 are linked to aggressive disease phenotypes, while PTEN and PIK3CA alterations are central to PI3K/AKT pathway dysregulation. Mismatch repair (MMR) genes—MLH1, MSH2, MSH6, PMS2—play critical roles in DNA repair, with mutations often associated with microsatellite instability and Lynch syndrome.
By including pharmacogenomics hotspots, the Endometrial Cancer NGS Panel also aids in assessing how patients metabolize chemotherapeutic agents, ensuring personalized and safer treatment strategies.
The truNGS® Endometrial Cancer Panel has been developed in accordance with NCCN and ESMO guidelines, ensuring its clinical relevance for oncology practice. The kit is validated for use with FFPE and fresh frozen tissue, requiring minimal input DNA (100–200 ng).
Its hybrid capture design guarantees complete exon coverage, making it possible to identify both established driver mutations and novel genetic changes. Compatible with Illumina and MGI sequencing platforms, the panel achieves mean target coverage of 1000x with approximately 2.0 million reads per sample.
The workflow is divided into two core stages:
Library Preparation – DNA is fragmented, adapters are ligated, and libraries undergo PCR amplification.
Hybrid Capture and Target Enrichment – Libraries are pooled and enriched with probes targeting the 31 marker genes and six PGx hotspots, followed by amplification.
Sequencing-ready libraries are run on Illumina or MGI platforms using 150 × 2 cycles chemistry. Data is processed through the integrated bioinformatics pipeline, which delivers accurate variant calling and generates a clinical-grade report within ~1.5 hours.
The Endometrial Cancer NGS Panel supports multiple applications in oncology and diagnostics:
Tumor profiling – Detect mutations that guide prognosis and therapeutic decisions.
Hereditary cancer testing – Identify MMR gene alterations associated with Lynch syndrome.
Pharmacogenomics analysis – Optimize drug dosing and safety by detecting clinically relevant PGx variants.
Translational research – Discover novel biomarkers and support clinical trial enrollment.
By combining accurate variant detection with integrated bioinformatics, the truNGS® Endometrial Cancer Panel provides clinicians and researchers with actionable insights to support personalized cancer care.
Product Catalogus
For any missing information or if you require additional details, please do not hesitate to contact us.